A Phase I Study of IBI325 in Patients With Advanced Solid Tumor
NCT05246995
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Solid Tumor
Interventions
DRUG:
IBI325+Sintilimab
Sponsor
Shandong Cancer Hospital and Institute